

Astellas Pharma Ltd

[View the current Astellas Pharma Ltd Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32167-Astellas+Pharma+Ltd.html)

(<http://www.bioportfolio.com/biocorporate/32167-Astellas+Pharma+Ltd.html>)

Contact Details:

Lovett House, Lovett Road,
Staines
MIDDLESEX
TW18 3AZ
United Kingdom

Tel: 44 1784 419400

Fax:

Email:

Astellas will seek to enhance its enterprise value in a sustainable manner. Astellas will seek to be the company of choice among all its stakeholders, including its customers, shareholders, employees and the global community. Astellas will strive to gain the trust of all stakeholders and thereby enhance its enterprise value.

Recent Publications by Astellas Pharma Ltd:



- [Disruption of the Ether-a-go-go K⁺ Channel Gene BEC1/KCNH3 Enhances Cognitive Function.](#)
*The K(+) channel, one of the determinants for neuronal excitability, is...*20th November, 2009
Drug Discovery Research, Astellas Pharma Inc., Ibaraki 305-8585, Japan,- J Neurosci. 2009 Nov 18;29(46):14637-14645. ([DOI Direct Link](#))
- [Response to the "Letter to the Editor of Pain" by Dr. Munro.](#)
*The K(+) channel, one of the determinants for neuronal excitability, is...*19th November, 2009
Pharmacology Research Labs., Drug Discovery Research, Astellas Pharma- Pain. 2009 Nov 16. ([DOI Direct Link](#))
- [A Comparison of Pharmacokinetics Between Humans and Monkeys.](#)
*To verify the availability of pharmacokinetic parameters in cynomolgus...*17th November, 2009
Astellas pharma Inc.- Drug Metab Dispos. 2009 Nov 12. ([DOI Direct Link](#))
- [Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.](#)
*(2S,4S)-4-Fluoro-1-([4-methyl-1-(methylsulfonyl)piperidin-4-yl]amino)acet...*12th November, 2009
Drug Discovery Research, Astellas Pharma Inc., 5-2-3, Toukoudai, Tuskuba,- Pharmacol Rep. 2009 Sep-Oct;61(5):899-908.
- [Optimization of \(4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene\)acetamide derivatives as](#)

[arginine vasopressin V2 receptor agonists and discussion of their binding modes.](#)

A series of...11th November, 2009

Drug Discovery Research, Astellas Pharma Inc, Tsukuba-shi, Ibaraki- Bioorg Med Chem. 2009 Dec 15;17(24):8161-7. Epub 2009 Oct 23. ([DOI Direct Link](#))

- [Time-dependent Inhibitory Effects of FK1706, a Novel Non-immunosuppressive Immunophilin Ligand, on CYP3A4/5 Activity in Humans in Vivo and in Vitro.](#)
*We investigated the inhibitory effects of FK1706, a novel...*6th November, 2009
1 Astellas Pharma, Inc.;- Drug Metab Dispos. 2009 Nov 4. ([DOI Direct Link](#))
- [Behavioral and Urological Evaluation of a Testicular Pain Model.](#)
*OBJECTIVES: To develop an animal model of testicular pain to examine the...*30th October, 2009
Pharmacology Research Labs, Astellas Pharma Inc, Ibaraki, Japan.- Urology. 2009 Oct 26. ([DOI Direct Link](#))
- [Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection.](#)
*Inosine 5'-monophosphate dehydrogenase (IMPDH) inhibition is a critical...*21st October, 2009
Pharmacology Research Laboratories, Astellas Pharma Inc., 21, Miyukigaoka,- Int Immunopharmacol. 2009 Oct 18. ([DOI Direct Link](#))
- [Characterization of human organic cation transporter 1 \(OCT1/SLC22A1\)-, and OCT2 \(SLC22A2\)-mediated transport of YM155 monobromide, a novel survivin suppressant.](#)
*YM155 monobromide,...*17th October, 2009
1 Astellas Pharma, Inc.;- Drug Metab Dispos. 2009 Oct 15. ([DOI Direct Link](#))
- [Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.](#)
*BACKGROUND: Valproic acid (VPA) is used to treat epilepsy and bipolar...*16th October, 2009
Drug Safety Research Laboratories, Astellas Pharma Inc., Yodogawa-ku,- Birth Defects Res B Dev Reprod Toxicol. 2009 Oct;86(5):394-401. ([DOI Direct Link](#))
- [Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.](#)
*BACKGROUND: Gastroesophageal reflux disease and acid-related conditions...*25th September, 2009
Astellas Pharma US, Inc., Deerfield, IL, USA.- Curr Med Res Opin. 2009 Nov;25(11):2703-9. ([DOI Direct Link](#))
- [Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure.](#)
*Sulfonylureas promote insulin secretion and potently lower blood glucose...*22nd September, 2009
Applied Pharmacology Research Labs, Drug Discovery Research, Astellas- Eur J Pharmacol. 2009 Nov 10;622(1-3):71-7. Epub 2009 Sep 17. ([DOI Direct Link](#))
- [Characterization of two models of drug-induced constipation in mice and evaluation of mustard oil in these models.](#)
*Although it is known that both clonidine and loperamide cause delayed...*16th September, 2009
Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.- Pharmacology. 2009;84(4):227-33. Epub 2009 Sep 10. ([DOI Direct Link](#))
- [Novel 7H-pyrrolo\[2,3-d\]pyrimidine derivatives as potent and orally active STAT6 inhibitors.](#)
*Signal transducers and activators of transcription 6 (STAT6) is an...*15th September, 2009
Drug Discovery Research, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba,- Bioorg Med Chem. 2009 Oct 1;17(19):6926-36. Epub 2009 Aug 15. ([DOI Direct Link](#))

Press Releases on Astellas Pharma Ltd:

Cytochroma to Present at 21st Annual Piper Jaffray Health Care Conference	25th November, 2009	Cytochroma	MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care
Cytochroma Announces Appointment of Peter Moldt to Board of Directors	25th November, 2009	Cytochroma	MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma today announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative on
Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis http://www
Reportlinker Adds Regenerative Medicine - Global Market Trends	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Regenerative Medicine - Global Market Trends http://www.reportlinker.com
Reportlinker Adds Pain Management - Global Trends	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Pain Management - Global Trends http://www.reportlinker.com/p0164220/Pain

BioNews Results for Astellas Pharma Ltd



- [Central Nervous System Disorders Therapy - Researchers from Astellas Pharma, Inc. discuss findings in central](#)
NewsRX: Nov 23 2009 8:31AM Matching: astellas pharma
- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome](#)
SmartBrief: Nov 20 2009 6:49AM Matching: astellas pharma
- [Rising Sun, Falling Stocks: Nintendo, Kyocera, Takeda Pharma, Nippon Telephone & Telegraph](#)
Guru Focus: Nov 20 2009 1:17PM Matching: astellas pharma
- [Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval](#)
News-Medical.Net: Nov 19 2009 12:49PM Matching: astellas pharma
- [XenoPort \(XNPT\) and Astellas Pharma Announce an Application for RLS Treatment XP13512 Filed with PMDA in Japan](#)
Street Insider: Nov 19 2009 12:21PM Matching: astellas pharma
- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP88](#)
Pharmacy Choice: Nov 19 2009 10:39PM Matching: astellas pharma
- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA](#)

[Approval of ASP88](#)

Genetic Engineering News: Nov 19 2009 1:59PM Matching: astellas pharma

- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP88](#)
Pharma Live: Nov 19 2009 1:14PM Matching: astellas pharma
- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA...](#)
Forbes.com: Nov 19 2009 12:01PM Matching: astellas pharma
- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome](#)
FinanzNachrichten.de: Nov 19 2009 11:40AM Matching: astellas pharma
- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome](#)
Stockwatch: Nov 19 2009 11:37AM Matching: astellas pharma
- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval](#)
PR inside: Nov 19 2009 11:36AM Matching: astellas pharma
- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP88](#)
NewsBlaze: Nov 19 2009 12:14PM Matching: astellas pharma
- [XenoPort, Astellas Pharma Submit NDA For ASP8825 For Restless Legs Syndrome In Japan - Quick Facts](#)
RTTNews.com: Nov 19 2009 12:11PM Matching: astellas pharma
- [Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome](#)
Business Wire UK: Nov 19 2009 11:35AM Matching: astellas pharma

Astellas Pharma Ltd Patents:



- 7250429- [Aminomethyl-substituted thiazolobenzimidazole compounds](#)
- 7317107- [Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity](#)
- 7335668- [Pharmaceutical composition for therapy of interstitial cystitis](#)
- 7341849- [Polynucleotides encoding SREB1 receptor](#)
- 7342117- [.alpha.-form or .beta.-form crystal of acetanilide derivative](#)
- 7351419- [Oral pharmaceutical suspension of Cefdinir crystal](#)
- 7358270- [Treating agent for irritable bowel syndrome](#)
- 7361658- [2-acylaminothiazole derivative or salt thereof](#)
- 7371842- [Polynucleotide encoding a 35 KDA protein that binds to WF00144](#)
- 7374923- [Polypeptide](#)
- 7375081- [Therapeutic combination of a pneumocandin derivative and an antifungal agent](#)
- 7317009- [Pyrrolopyridazine derivatives](#)
- 7314862- [Antitumor agent](#)
- 7314719- [Method for increasing productivity of secondary metabolite by conferring drug-resistant mutations](#)
- 7255876- [Composition comprises sustained-release fine particles and manufacturing method thereof](#)

- 7264935- [Potassium-dependent sodium-calcium exchanger](#)
- 7265120- [Pyrazine derivatives and pharmaceutical use thereof](#)
- 7273951- [Polyhydroxy phenols and their use in binding p-selectin](#)
- 7285554- [Pyrazole derivative](#)
- 7297698- [N-phenyl-\(2R,5S\) dimethylpiperazine derivative](#)
- 7304039- [Glucose-based compounds with affinity to P-selectin](#)
- 7307072- [Oral pharmaceutical suspension of Cefdinir crystal](#)
- 7307074- [Diazepam derivatives or salts thereof](#)
- 7309710- [Crystals](#)
- 7375222- [2,4,6-Triamino-1,3,5-triazine derivative](#)
- 7396665- [Method of producing FR901228](#)
- 7488739- [Quinolone derivative or salt thereof](#)
- 7504417- [Substituted benzene derivatives or salts thereof](#)
- 7531516- [Peptidic compounds selectively binding to P-selectin](#)
- 7557112- [Aromatic-ring-fused pyrimidine derivative](#)
- 7557127- [HDAC inhibitor](#)
- 7569688- [Propane-1, 3-dione derivative](#)
- 7575762- [Composition comprises sustained-release fine particles and manufacturing method thereof](#)
- 7585878- [Benzamide derivative or salt thereof](#)
- 7585886- [Pyrrolidine derivative or salt thereof](#)
- 7605131- [EML4-ALK fusion gene](#)
- 7476508- [Method of screening agent for improving memory and learning ability](#)
- 7465748- [Amide derivative](#)
- 7465731- [HDAC inhibitor](#)
- 7399587- [Canine CYP1A2 genetic polymorphism](#)
- 7402406- [Methods of evaluating phosphatase inhibitors](#)
- 7405051- [Method of screening antiplatelet agents](#)
- 7407961- [Pyrazine derivatives and pharmaceutical use thereof](#)
- 7417060- [Aminoalcohol derivatives](#)
- 7442387- [Pharmaceutical composition for controlled release of active substances and manufacturing method thereof](#)
- 7442715- [Thiazole derivatives](#)
- 7449456- [Diaminopyrimidinecarboxamide derivative](#)
- 7452983- [Protein which binds to Akt2](#)
- 7459451- [Pyrazolopyridine derivatives](#)
- 7608280- [Method of producing FR901228](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic

- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

